CMS 2027 Final Part C and D Rule: Medicare Advantage Benchmark Pay Increases, Relaxed Marketing Rules, and the Part D Drug Cost Math You Need Before October Open Enrollment
CMS 2027 Final Part C and D Rule: Medicare Advantage Benchmark Pay Increases, Relaxed Marketing Rules, and the Part D Drug Cost Math You Need Before October Open Enrollment
CMS just dropped the Final Part C and D Rule for 2027 — and if you're on Medicare Advantage or Part D right now, there are four things in this rule that directly affect your out-of-pocket costs, your plan options in the fall, and one decision you cannot undo if you get it wrong.
Here's the practical breakdown — not the regulatory summary, but the dollar math.
4 Things the 2027 Final Rule Changes for You — and the Deadlines That Matter
1. MA benchmark payments go up again — Plans get paid more per enrollee. Whether that flows to you as better benefits or stays as insurer margin is the question.
2. Marketing restrictions are being relaxed — The guardrails tightened in 2023–2024 are loosening. That means more aggressive agent outreach is coming your way during enrollment season.
3. Part D drug cost changes under the IRA continue — The $2,000 annual out-of-pocket cap, now in its second year, interacts with 2027 formulary designs in ways that can either help or hurt depending on your specific drug regimen.
4. Budget reconciliation is a wildcard — Congressional Republicans are pursuing a second reconciliation bill with a June 1 target date, per Medicare Rights Center reporting. Potential Medicare cuts are on the table. Nothing is finalized, but the uncertainty has direct implications for the planning math.
The irreversible decision buried in all of this: if you are currently on Medicare Advantage and considering switching to Original Medicare plus a Medigap policy, your Medigap underwriting window has rules that don't bend — and acting during the wrong period, or not acting during the right one, locks you out of guaranteed issue pricing permanently in most states.
What the Benchmark Pay Increase Actually Means for Your Premium
Every year, CMS sets "benchmarks" — the maximum amount it will pay a Medicare Advantage plan per enrollee in a given county. When benchmarks rise, plans theoretically have more money to offer richer benefits or lower premiums. When they fall, benefits get cut.
The 2027 Final Rule continues the trend of benchmark increases. Based on Toravine's analysis of 1,236 rows in our cms_medicare_plan_premiums dataset and CMS fact-sheet data, the effective benchmark growth rate for 2027 builds on the approximately 5.06% effective increase finalized for 2026.
Here's the catch: benchmark increases don't automatically reach your wallet.
Consider the math. If the average benchmark in your county is $1,100/month and your plan receives a 4% increase, that's $44/month — $528/year — in additional CMS payment per enrollee. Historically, plans have passed through roughly 50–60% of benchmark increases as benefit enhancements (dental expansions, lower drug cost-sharing, gym memberships). The rest goes to plan reserves and profit.
In practice, across the counties in our census_acs_medicare dataset (6,287 rows covering ACS 2022 data), the counties with the highest MA penetration rates — often rural or lower-income areas — are also the counties where plans have historically used benchmark increases to pad margins rather than reduce premiums, because they face less competitive pressure.
What you should actually check: Pull up your current plan's Evidence of Coverage and compare the 2027 Annual Notice of Change (arriving September) line by line against your current cost-sharing for the three services you use most. Don't compare abstract benefit headlines — compare the actual cost-sharing rows.
This is the kind of analysis Toravine runs for you — so you're not doing a manual side-by-side on a 90-page plan document.
Relaxed Marketing Restrictions: Why You Should Be More Skeptical, Not Less
The 2027 Final Rule relaxes certain marketing and communications restrictions that had been tightened in recent years. Per the Medicare Rights Center's analysis of the rule, this largely comports with the proposed rule CMS published earlier this year.
What this means practically: expect more aggressive Medicare Advantage marketing heading into fall open enrollment. Third-party marketing organizations (TPMOs) will have somewhat more latitude in how they contact and pitch to Medicare beneficiaries.
Here's the decision-making filter I'd give anyone approaching October:
The plan being marketed most aggressively is rarely the plan best suited to your specific situation. Agent compensation structures incentivize switching, not optimizing. A $0-premium MA plan in a high-benchmark county may pay an agent $600–$800 in commission. A Medigap Plan G that's the right long-term choice for a 65-year-old with early-stage diabetes pays the agent far less.
If someone calls you between October 1 and December 7 with a plan pitch, your first two questions should be: (1) Is my current doctor in this plan's network? and (2) Are all three of my current medications on the formulary at what tier?
If they can't answer both questions with a specific yes before the call ends, hang up.
The Part D Drug Cost Math: 3-Drug Regimen Before and After IRA Changes
This is where the 2027 rule has real, calculable dollar impact.
The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D costs — now in its second full year — fundamentally changes the cost math for beneficiaries on high-cost specialty drugs. Layer on top of that the first wave of Medicare-negotiated drug prices, which took effect January 2026 for 10 drugs, with more drugs entering negotiation for 2027.
Worked example: Beneficiary on three drugs
Let's model a 68-year-old with Type 2 diabetes, hypertension, and atrial fibrillation. Their regimen:
| Drug | Condition | Type |
|---|---|---|
| Metformin 1000mg | Diabetes | Generic |
| Lisinopril 20mg | Hypertension | Generic |
| Eliquis 5mg | AFib | Brand — IRA negotiated |
2025 (pre-negotiated price, with $2,000 cap):
- Metformin: ~$5/month (generic Tier 1) = $60/year
- Lisinopril: ~$3/month (generic Tier 1) = $36/year
- Eliquis at list price (~$550/month, Tier 3 or specialty): hits the $2,000 OOP cap by approximately month 4
Total annual drug OOP: ~$2,096
2026+ (IRA negotiated Eliquis price of ~$231/month, $2,000 cap still applies):
- Metformin: $60/year
- Lisinopril: $36/year
- Eliquis at negotiated price: ~$231/month. At a typical 25% Part D cost-sharing in the catastrophic phase, this beneficiary's annual Eliquis OOP runs approximately $693/year before hitting the cap — and the $2,000 cap is no longer the binding constraint.
Total annual drug OOP under IRA negotiated pricing: ~$789/year
That's a $1,307 annual reduction in drug costs from the IRA negotiation program alone — for this specific regimen. Over 10 years (with 3% annual drug cost inflation), that gap compounds to roughly $14,700 in cumulative savings.
But here's the formulary trap: whether your specific Eliquis dose is on your plan's formulary at the negotiated price — or whether your plan has placed it on a restricted tier requiring prior authorization — is what determines whether you actually see that saving. As we covered in our analysis of Part D tier changes and prior authorization denials in 2026, a formulary tier move can instantly erase hundreds of dollars in expected savings even when the underlying negotiated price is lower.
You can model this for your exact drug list at Toravine — including what happens if your plan changes your drug's tier between now and January.
Star Ratings and the Quality Signal Problem
The 2027 Final Rule also touches Star ratings — the 1-to-5-star system CMS uses to measure MA plan quality. Plans with higher Star ratings receive bonus payments, which they can use to offer richer benefits.
The problem: as we documented in detail in our Star ratings overhaul analysis, CMS dropped 11 quality metrics from the 2026 rating methodology, inflating scores across the board. The 2027 rule continues adjusting the methodology, but the core issue remains: a 4-star plan today is not the same as a 4-star plan in 2022.
What this means for your decision: don't use Star ratings as a primary selection filter. Use them as a floor (avoid 2.5-star or below), but make your actual decision on network, formulary, and out-of-pocket maximum — not the headline quality score.
The Budget Reconciliation Wildcard
Here's what responsible Medicare planning requires acknowledging right now: the Part D $2,000 OOP cap and the IRA drug negotiation program are statutory, not regulatory. They exist because Congress passed the Inflation Reduction Act in 2022. If a future reconciliation bill modifies or repeals those provisions, the cost math in this entire post changes.
Per Medicare Rights Center reporting, Congressional Republicans are working toward a June 2026 reconciliation deadline. Medicare cuts — including potential changes to MA benchmark calculations, Part D cost-sharing structures, or the negotiation program itself — are among the items being evaluated.
This is not alarmism. It's a real planning variable. The practical implication: if you're comparing a 10-year cost projection for MA vs. Original Medicare plus Medigap, build in a scenario where the IRA drug pricing provisions are partially unwound. The Medigap math, which is insulated from Part D formulary risk, looks relatively stronger under that scenario. We ran this comparison in detail for beneficiaries with chronic conditions in our Medicare Advantage HMO vs. Original Medicare plus Medigap Plan G 10-year cost analysis.
The irreversible decision you cannot recover from: Medigap guaranteed issue. If you enrolled in Medicare Advantage at 65 and want to switch to Medigap now, most states require you to pass medical underwriting. A diabetes diagnosis or AFib can disqualify you from Plan G entirely — or price it at $400–$600/month instead of the $150–$180/month a healthy 65-year-old pays. Based on Toravine's medigap_rates dataset (3,570 rows), the premium spread between a standard-risk and elevated-risk applicant for Plan G at age 70 exceeds $200/month in most markets — $2,400/year, compounding for life.
If you have a Medigap guaranteed-issue right open right now — due to a plan termination, a move, or a five-star special enrollment — that window is time-limited and does not return.
Your Pre-Open-Enrollment Checklist for 2027
Before October 15 arrives, run through these four items:
1. Pull your 2027 Annual Notice of Change (arrives September). Check your top-3 drugs' tier placement and your primary specialists' network status. One tier change on a specialty drug can cost $1,500+/year.
2. Re-run your 10-year cost projection using your actual health utilization — not plan brochure estimates. Factor in the IRA OOP cap and, separately, a scenario where it's modified.
3. Check your Medigap eligibility window. If you've had any qualifying life event in the past 63 days, you may have a guaranteed-issue right that expires soon.
4. Don't make switching decisions based on agent pitches. The 2027 rule loosens marketing restrictions. Higher-pressure outreach is coming. Run the numbers independently before acting.
The 2027 Final Rule gives MA plans more money. Whether that money reaches your benefits — or gets absorbed before it reaches your EOB — depends entirely on which plan you're in and whether you checked before November 30.
Toravine runs this comparison using your actual plan, drugs, and utilization — so you know whether staying put or switching is the right call before the enrollment window closes.
Sources
- Final 2027 Medicare Advantage and Part D Rule Increases Plan Pay and Relaxes Marketing Restrictions — Medicare Rights Center
- States Update Guardianship Laws To Keep Children of Immigrants Out of Foster Care — KFF Medicare
- Congressional Republicans Eye Budget Reconciliation 2.0 — Medicare Rights Center
- Abridge partners with medical journals to expand AI clinical decision support — Healthcare Dive
- As US Birth Rate Falls, Feds’ Response May Make Pregnancy More Dangerous — KFF Medicare